ArticleJMIR formative research2022
Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring-Driven Virtual Care Program: Prospective Study.
Article in JMIR formative research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03865381 (Onduo Virtual Diabetes Clinic Study), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Onduo Virtual Diabetes Clinic Study
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Impact of Real-Time Continuous Glucose Monitoring on Medication Use and Glycemic Control in Type 2 Diabetes Across Therapy Regimens.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Continuous glucose monitoring guides glucagon-like peptide 1-based therapy use and optimization in people with type 2 diabetes.Journal of family medicine and primary care · 2025Article
- Continuous Glucose Monitoring (CGM) as a Behavior Modification Tool: A Case Series on CGM-Guided Nutrition in People With Type 2 Diabetes Not Using Insulin.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement.Frontiers in endocrinology · 2023Review
- Mobile-Based Medication Management Applications: A Scoping Review of Functional and Non-Functional Requirements.Healthcare technology lettersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Onduo virtual care program for people with type 2 diabetes (T2D) includes a mobile app, remote lifestyle coaching, connected devices, and telemedicine consultations with endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices. In a previously described 4-month prospective study of this program, adults with T2D and baseline glycated hemoglobin (HbA
objectiveThe objective of this analysis was to evaluate medication optimization and management in the 4-month prospective T2D study.
methodsStudy participants received at least 1 telemedicine consultation with an Onduo endocrinologist for diabetes medication management and used RT-CGM intermittently to guide therapy and dosing. Medication changes were analyzed.
resultsOf 55 participants, 48 (87%) had a medication change consisting of a dose change, addition, or discontinuation. Of these, 15 (31%) participants had a net increase in number of diabetes medication classes from baseline. Mean time to first medication change for these participants was 36 days. The percentage of participants taking a glucagon-like peptide-1 receptor agonist increased from 25% (12/48) to 56% (n=27), while the percentages of participants taking a sulfonylurea or dipeptidyl peptidase 4 inhibitor decreased from 56% (n=27) to 33% (n=16) and 17% (n=8) to 6% (n=3), respectively. Prescriptions of other antidiabetic medication classes including insulin did not change significantly.
conclusionsThe Onduo virtual care program can play an important role in providing timely access to guideline-based diabetes management medications and technologies for people with T2D.
trial registrationClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.